

RETRACTED ARTICLE: Histone Demethylase KDM3A Promotes Cervical Cancer Malignancy Through the ETS1/KIF14/Hedgehog Axis

This article was published in the following Dove Press journal: OncoTargets and Therapy

Jinyu Liu^{1,*}
Dongqing Li^{2,*}
Xin Zhang³
Yanyan Li¹
Jian Ou⁴

¹Frist Department of Gynecologic Oncology, Jilin Cancer Hospital, Changchun 130012, Jilin, People's Republic of China; ²Second Department of Gynecologic Oncology, Jilin Cancer Hospital, Changchun 130012, Jilin, People's Republic of China; ³Department of Rheumatology and Immunology, China-Japan Union Hospital of Jilin University, Changchun 130033, Jilin, People's Republic of China; ⁴Department of Gynecological Oncology Radiotherapy, Jilin Cancer Hospital, Changchun 130012, Jilin, People's Republic of China

*These authors contributed equally this work



Correspondence: Jian Ou Department of Gynecological Oncology Radiotherapy, Jilin Cancer Hospital, No. 1018, Huguang Road, Changchun 130012, Jilin, People's Republic of China Tel/Fax +86-18686500760 Email Oujian4184@163.com **Background:** Lysine demethylase 3A (*KDM3A*) has been increased fecognized as an important epigenetic regulator involved in cane redevelopment. This study aims to explore the relevance of *KDM3A* to cervical cancer (*CC*) per ession appoint molecules involved.

Materials and Methods: Tumor and to adjacent tissues from CC patients were collected. *KDM3A* expression in tissues and the cellulines and its correlation with the survival and prognosis of patients were determined. Malignal potentials of CC cells and the angiogenesis ability of HUVECs were method to evaluate the anction of *KDM3A* on CC progression. The interactions among *KLM3A*, H3K9rc12 and *ETS1*, and the binding between *ETS1* and *KIF14* were validated through ChIP and beiferase assays. Altered expression of *ETS1* and *KIF14* was introduced to express their roles in CC development.

Results: *KDM3*: We chundantly expressed in CC tissues and cells and linked to dismal prognosis of CC patients and Edown of *KDM3A* suppressed malignant behaviors of CC cells. *KEV3A* was found to increase *ETS1* expression through the demethylation of H3K me2. Verexpression of *ETS1* blocked the inhibiting roles of sh-KDM3A. *ETS1* and did in the proporter region of *KIF14* to trigger its transcription. Overexpression of *KIF14* to trigger its transcription. Overexpression of *KIF14* to trigger its transcription of the proporter region of *KIF14* to trigger its transcription. Overexpression of *KIF14* and it activated the Hedgehog signaling pathway. Artificial activation of Hedgehog Sag1.5 diminished the effects of sh-KDM3A. These changes were reproduced the proportion of the proportion of the proportion of the degenog signaling pathway. Artificial activation of the degenog Sag1.5 diminished the effects of sh-KDM3A. These changes were reproduced the proportion of the proportion of the degenog signaling pathway.

Collusion: This study evidenced that *KDM3A* promotes *ETS1*-mediated *KIF14* transcription to promote CC progression with the involvement of the Hedgehog activation.

Keywords: lysine demethylase 3A, ETS proto-oncogene 1, kinesin family member 14, Hedgehog signaling pathway, cervical cancer

Introduction

Cervical cancer (CC) represents the fourth gynecological malignancy both in terms of incidence and mortality among females, with an estimated 570,000 diagnoses and 311,000 deaths in 2018 across the globe. Specifically, the morbidity rate varies worldwide, with the highest rate in Eastern Africa and the lowest incidence in Western Asia; and it is the second most prevailing cancer in women in South East Asia. Chemo- and radiotherapies are well recognized as the primary interventions for CC control, but the overall survival rate of the advanced patients who underwent these conventional therapies are still low, at about 40%. Besides, the radiation exposure itself may bring side-effects and a risk fact for cancer development.

Gene-based therapy has been accepted as a less-invasive promising approach that brings the development of many treating options focusing on different aspects,⁵ which requires an increased understanding in the molecules of action.

Though initially less studied, the epigenetic mechanisms which mediate transcriptional regulation and dysregulation in cancer have aroused increasing focus among researchers in this field, mainly including the acetylation and methylation modifications.⁶ Lysine demethylase 3A (KDM3A), also termed Jumonji domain-containing 1A (JMJD1A) and Jumonji C (domain-containing histone demethylase 2A) JHDM2A, is a histone H3 lysine 9 (H3K9) dimethyl and monomethyl (me2/1) demethylase has been implicated in many cellular processes from proliferation to progression, and is reported as an advanced target for cancer treatment. 7,8 But the role of KDM3A in CC development remains less concerned. Interestingly, a previous report suggested that KDM3A could interactwith the ETS proto-oncogene transcription factor 1 (ETS1) flanking its start site through a H3K9me2 demethylation manner, which leads to the further metastasis of Ewing sarcoma cells. ETS1 is a key member of the ETS domain family and is implicated in many essential processes cancer development, such as invasion, epithelial-to mesenchymal transition (EMT), drug-resist and angiogenesis. 10 Similarly, it was dependent as a promising therapeutic target for CC as 11 W fore speculated that there is a similar interact. between KDM3A and ETS1 in CC despendent. A previous study noted that E1SI can comote the transcription activity of kinesis ramily member 14 (KIF14), 12 which has been documented to be abundantly expressed in CC and associated with there resistance and unfavorable prognosis. 13 The possibly regulates XIF14 anscripto to govern CC development. Hence this performed in both cell and animal models validate the functions of the above factors in CC prosssion and their interactions, as well as the potential pathway implicated.

Materials and Methods

Ethics Statement

The study was performed as per the Declaration of Helsinki and ratified by the Ethics Committee of Jilin Cancer Hospital. All patients signed an informed consent form before enrollment. The animal experimental protocol

was approved by the Committee on the Ethics of Animal Experiments of Jilin Cancer Hospital. All animal procedures were performed in line with the Guide for the Care and Use of Laboratory Animals published by National Institutes of Health (NIH Publication No.85-23, revised 1996). Great efforts were made to reduce the usage and pain in animals.

Sample Collection

Tumor tissues and the adjacent tissues were collected from 50 CC patients who were treated in ncer Hospital from January 2013 to April 2014 the first-till diagnosed patients with complete clinical in rmation we free of any other malignancies or mistory or reoperative radiotherapy and chemother by. The tissues ere collected during surgery and instally reserved at -80°C. A 5-year follow-up study as perfored.

Cell Transfection

mortalized cervice epithelial cell line (H8) was Cell Reserve Center, the Chinese Academy of es (Shanghi, China), and CC cell lines (HT-8, CaSki, VeLa and SiHa) were from American Type Yure Collection (ATCC, Manassas, VA, USA). All is wee cultivated in 10% fetal bovine serum (FBS)supplemented DMEM containing 1% penicillin/streptomyin (all from Sigma-Aldrich Chemical Company, St Louis, MO, USA) at constant 37°C with 5% CO₂. The medium was refreshed every 3 days.

HeLa and SiHa cells were used for the following transfection. The short hairpin (sh) RNAs targeting KDM3A (sh-KDM3A1, 2#), overexpressing vector of ETS-1 (oe-ETS1) and KIF14 (oe-KIF14), and the corresponding control vectors were acquired from GenePharma Co., Ltd. (Shanghai, China). All transfection was performed in line with the protocols of a Lipofectamine 2000 kit (Thermo Fisher Scientific Inc., Waltham, MA, USA). A Hedgehog pathway-specific agonist Sag1.5 (HY-124,899) acquired from MedChemExpress (Monmouth Junction, NJ, USA) was used to activate the Hedgehog pathway in CC cells, and dimethyl sulphoxide (DMSO, Sigma-Aldrich) served as a control.

Reverse Transcription Quantitative Polymerase Chain Reaction (RT-qPCR)

An RNeasy Mini Kit (Qiagen Sciences, Valencia, CA, USA) was utilized to extract total RNA from cells or tissues. Then,

1.5 μ g RNA was reversely transcribed to cDNA using the TaqMan Reverse Transcription Reagent (Applied Biosystems Inc., Carlsbad, CA, USA). Then, real-time qPCR was performed on a Prism 7900HT System (Applied Biosystems) and a SYBR Green PCR Master Mix (Applied Biosystems). The $2^{-\Delta\Delta Ct}$ method was used to determine gene expression. The primers are exhibited in Table 1, and *GAPDH* served as an internal reference.

Immunohistochemical (IHC) Staining

The tumor samples were fixed in paraformaldehyde, embedded in paraffin, cut into sections (4 μ m), dewaxed, and rehydrated. Then, the sections were soaked in boiled 10 mM citrate buffer (pH=6.0) for 2 minutes of antigen retrieval, and then blocked with 100 μ L H₂O₂ for 10 minutes. Then, the sections were co-cultured with the primary antibodies against KDM3A (1:50, ab91252, Abcam Inc., Cambridge, MA, USA), ETS1 (1:500, ab220361, Abcam), KIF14 (1:100, #PA5-87,769, Thermo Fisher) and Gli1 (1:200, #MA5-32,553, Thermo Fisher) at 4°C overnight, and then with the secondary antibodies anti-mouse IgG H&L (HRP)

Table I Primer Sequences for RT-qPCR

Gene	Primer Sequence (5'-3')
KDM3A	F: GCCAACATTGGAGACA, TCTG R: CTCGAACACCTT GACAG TCG
ETSI	F: GAGTCAACCCA CTA LCAG. R: GAGCGT GATAGG TCTGTG
KIF14	F: GCA , TTX TGAACAAGC , ACCA R: ATGTTGCTG , AGCGGGACTAA
Вах	. TCAGGATGCGTCCACCAAGAAG R: TG7_ATCCACGGCGGCAATCATC
Bcl2	R: CA SAGAAATCAAACAGAGGC
E-cadho	R: TGGCAGTGTCTCTCCAAATCCG
N-cadherin	F: CCTCCAGAGTTTACTGCCATGAC R: GTAGGATCTCCGCCACTGATTC
Vimentin	F: AGGCAAAGCAGGAGTCCACTGA R: ATCTGGCGTTCCAGGGACTCAT
GAPDH	F: GTCTCCTCTGACTTCAACAGCG R: ACCACCCTGTTGCTGTAGCCAA

Abbreviations: RT-qPCR, reverse transcription quantitative polymerase chain reaction; KDM3A, lysine demethylase 3A; ETS-I, ETS proto-oncogene transcription factor I; KIF14, kinesin family member 14; Bcl-2, B-cell lymphoma-2; Bax, Bcl-2-associated X; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; F, forward; R, reverse.

(ab205719, Abcam) and goat anti-rabbit IgG H&L (HRP) (ab6721, Abcam) at 20°C for 1 hour, followed by a 10-min ute incubation with horseradish peroxidase (HRP)-labeled streptomycin (KIT-9710, MXB Biotechnologies, China). The staining was developed by 3.3'-diaminobenzidine, and the tissues were observed under a microscope (Nikon Eclipse NI, Japan).

Western Blot Analysis

Tissues and cells were collected by proteinase inhibitorcontained radio-immunoprecipitation assay (RIPA) cell lysis buffer on ice. After Totein untification by a bicinchoninic acid (BCA) it (Pierce altham, MA, USA), an equal volum of protectives was separated by 8–12% SDS-PACE and transfer dente PVDF membranes (Millipore, illeri, MA, USA). Next, the membranes were locked 4th 5% skimmed milk for 15 minutes a sultured with primary antibodies against KDM3A (1:1, 0, ab91252, Abcam), ETS1 (1:1,000, H3K9me2 (1:1,000, ab1220, 1, Abcar bcam), GAPDH (1:10,000, ab181602, Abcam), Gli1 1:1,000, #A5-32,553, Thermo Fisher), and Gli3 1,500, ab 1130, Abcam) at 4°C overnight, followed ncubation with the secondary antibodies antise IgG H&L (HRP) (ab205719, Abcam) and goat anti-rabbit IgG H&L (HRP) (ab6721, Abcam) at 20°C for 1 hour. Then, the blot bands were developed by enhanced chemiluminescence (ECL) reagent (Millipore) and scanned using an immune blotting system (Tanon 5200, China).

Cell Counting Kit-8 (CCK-8) Method

A CCK-8 kit was used to measure cell proliferation. Briefly, transfected cells were sorted into 96-well plates at 2,000 cells per well. Then, each well was loaded with $10 \mu L$ CCK-8 solution at different time points for another 2 hours of incubation at 37° C. The optical density (OD) at 450 nm was determined utilizing a spectrophotometer (Synergy H1, Bio-Tek, USA).

Colony Formation Assay

After transfection, cells were sorted in 6-well plates at 1×10⁵ cells per well for 2 weeks of incubation. Then, the cells were immobilized in 4% paraformaldehyde for 30 minutes and stained with crystal violet (Sigma-Aldrich) for 15 minutes, and the number of colonies (over 50 cells) were observed under an inverted microscope (Olympus Optical Co., Ltd, Tokyo, Japan) with five random fields observed.

5-Ethynyl-2'-Deoxyuridine (EdU) Labeling **Assay**

A Cell-Light EdU DNA cell proliferation kit (RiboBio, Guangzhou, China) was used for DNA replication and proliferation measurement. Cells were sorted in 96-well plates at 2×10⁴ cells per well. After 36 hours, each well was filled with 50 µM EdU solution for another 3 hours of incubation. Then, the cells were fixed and stained by Apollo solution. Nuclei were stained by 4', 6-diamidino-2-phenylindole (DAPI), and the staining images were captured under the inverted microscope. Five random fields were included, and the red staining (EdU-positive cells) and blue staining (DAPI-stained cells) were calculated.

Terminal Deoxynucleotidyl Transferase (TdT)-Mediated dUTP Nick End Labeling (TUNEL)

Apoptosis of cells was determined using a TUNEL kit from Beyotime Biotechnology Co., Ltd. (Shanghai, China). Briefly, cells were immobilized for 30 minutes and cultured in phosphate buffer saline (PBS) containing 0.3% Triton X-100 for 5 minutes of incubation. Then, the cells were additionally incubated with 50 µL fresh TUN reagent at 37°C avoiding light exposure for 60 minute. Thereafter, the slides were anti-quenched by fluorescent mounting media, and the relative fluorescence in sity was determined by an EVOS FL microscope (Invited in the Invited in Thermo Fisher).

Flow Cytometry

An Annexin V-fluorescein in hiocyanate (TC) apoptosis detection kit (Thermo sher) was used or apoptosis detection. Briefly, cells fter to sfection were centrifuged at 1,000 g for 5 minutes on the sernatant discarded. Next, the cell were suspen d. PBS, and the suspension containing 5×1 cells was centrifuged again to discard the super that, Then, the cells were resuspended in the Annexin V-F. C mixture and then stained with propidium iodide (PI) solution for 10–20 minutes of incubation at 20-25°C in dark condition. Cell apoptosis was evaluated using a flow cytometer (FACS Calibur, BD Biosciences, San Jose, CA, USA), and the data were analyzed by Flow J.

Wound-Healing Assay

Cells were sorted in 6-well plates. When the cell confluence reached 90-100%, a scratch was produced on the cells using a 200 µL pipette tip. Thereafter, the cells were cultured in FBS-free medium containing berberine chloride hydrate, an inhibitor for cancer cell growth (Gibco Company, Grand Island, NY, USA). The scratch width was measured at 0 and 48 hours using an inverted microscope (Olympus), and the migration rate of cells was evaluated by Image J.

Transwell Assay

Cell invasion was measured by a Transwell assay. The apical chambers (Millipore) were coated with Matrigel (BD Biosciences). Ther each appl chamber was filled with 200 µL serum-free ell suspensi containing 1×10⁵ transfected cells thile each basola ral chamber was added with 60% aL 10% FBS- W.M. After 24 hours of incubation at 7°C, 11 non-invaded cells on the upper membrane were weed out sing cotton swabs, while the invest cells were first for 30 minutes and stained by crystal let for 20 minutes. The cells were observed er the inved microscope, and the average valu of five included fields of views was calculated.

Tub Formation Assay

mical vein endothelial cell (HUVEC) line from ATCC was used for angiogenesis meaarement. The cells were sorted in Matrigel-coated (90 L) 24-well plates at 37°C for 30 minutes for polymerizaon, and then seeded into wells filled with different HeLa and SiHa cell-conditioned media. After a further 6 hours of incubation, the tube formation by HUVECs was imaged under the inverted microscope.

Immunofluorescence Staining

CC cells were fixed and permeated in 0.1% Triton X-100 for 30 minutes. After blockade by 5% skimmed milk, the cells were cultivated with anti-KDM3A (ab243641) and anti-ETS1 (ab186844) at 4°C overnight, and then with goat anti-rabbit IgG H&L (Alexa Fluor® (ab150077) at 20°C for 1 hour. Then, the cells were rinsed and counterstained with 4',6-diamidino-2-phenylindole (DAPI, Sigma-Aldrich), and observed by a fluorescence microscope (Olympus). All antibodies were from Abcam.

Luciferase Reporter Assay

The putative binding sites between ETS1 and the promoter region of KIF14 were obtained from a bioinformatics system Jasper (http://jaspar.genereg.net/). The binding sites were PCR amplified and inserted to pGL3 vectors

(Promega, Corp., Madison, WI, USA) to construct *KIF14* promoter luciferase vectors (named Promoter). Then, the promoter was co-transfected with either oe-ETS1 or oe-NC into 293T cells (ATCC). Forty-eight hours later, the luciferase activity was determined using a Luciferase Reporter Assay System (Promega).

Chromatin Immunoprecipitation (ChIP) Assay

An EZ-Magna ChIP kit (EMD Millipore) was used to verify the interactions among *KDM3A*, and the promoter region of *ETS1* and *KIF14*. Briefly, CC cell lines were incubated in 1% formaldehyde solution for 15 minutes of crosslink and then quenched by glycine. Following ultrasonication, the DNA fragments were obtained. Specifically, for the binding relationship between *KDM3A* and *ETS1*, the promoter of *ETS1* was enriched by the magnet beads conjugated with anti-KDM3A in

HeLa cells, while that was enriched by the magnet beads conjugated with anti-H3K9me2 in SiHa cells. For the binding relationship between *ETS1* and *KIF14*, the promoter of *KIF14* was enriched by the magnet-beads conjugated with anti-ETS1 in both HeLa and SiHa cells. Magnet beads conjugated with IgG served as a control. The precipitated chromatin DNA was analyzed by RT-qPCR.

Xenograft Tumor in Nude Mice

Twenty NU-Foxn1^{nu} mice (4–6 weeks old) were from Vital River Laboratory Animals and oldy Co., Ltd. (Beijing, China). HeLa and a Ha cells with stable sh-KDM3A or sh-NC transfection were imported into the mice through a subcuta eous injection. From the 10th day after cell implantation, the two or size as measured using a vernier caliper event 5 days. The tumor volume (V) was determined a follows. K=lengt width²×0.52. The mice were eutrained through the overdose of pentobarbital




Figure 1 *KDM3A* is abundantly expressed in CC and indicates a dismal prognosis in patients. (**A**) mRNA expression of *KDM3A* in CC and adjacent tissues determined by RT-qPCR (n=50); (**B**) staining intensity of *KDM3A* in CC tumor and the adjacent tissues by IHC staining (n=50); (**C**) correlation between *KDM3A* expression and the 5-year survival rate in CC patients. In panels (**A**) and (**B**), data were analyzed by paired *t* test, ***P*<0.01; in panel (**C**), correlation was analyzed by the Log-rank (Mantel-Cox) test, ***P*<0.05.

OncoTargets and Therapy 2020:13

submit your manuscript | www.dovepress.com
DovePress

sodium (150 mg/kg, intraperitoneal injection) on the 30th day. Then, the tumors were collected and weighed for histological examination.

Statistical Analysis

Prism 8.0 (GraphPad, La Jolla, CA, USA) was used for data analysis. Data were obtained from no less than three independent experiments and presented as mean±standard deviation (SD). Differences were analyzed by paired *t*-test (two groups) and one-way or two-way analysis of variance (ANOVA), followed by Tukey's multiple test (over two groups). The Log-rank (Mantel-Cox) test was used to record the survival rate of patients. Enumeration data were analyzed by Fisher's exact test. The correlations between variables were evaluated by Spearman's rank correlation coefficient. *P<0.05 represents statistical significance.

Results

KDM3A is Abundantly Expressed in CC Tissues and Indicates a Dismal Prognosis in Patients

Though the oncogenic roles of *KDM3A* have been motioned, its function in CC remains largely unknown. Here we first examined mRNA expression of *KDM2* (in the tumor tissues and the paired adjacent tissues from . CC patients, which suggested that the *KDM3* expression in CC tissues was increased (Figure 1A) Base of this, the following IHC staining results should that the staining

intensity of *KDM3A* was higher in tumor tissues than in the adjacent tissues (Figure 1B). According to the average value (2.9) of *KDM3A* expression in tumor tissues, the included patients were allocated into the high *KDM3A* expression group (n=25) and poor *KDM3A* expression group (n=25). It was found that CC patients with higher *KDM3A* expression had a significantly worse 5-year survival rate (Figure 1C). The clinical characteristics of patients are exhibited in Table 2, which suggested that a high *KDM3A* expression profile in patients was correlated with worse clinical presentation.

Knockdown of M34 Suppresses CC Cell Growth

Following the ordings above we men measured expression of *KDM3A* in 18 and CC cell lines (HT-8, CaSki, HeLa, call-SiHa). It was found that the mRNA and proton expression of KDM3A was notably increased in CC cell lines compared to that in H8 cells (Figure 2A and 1). The He a and SiHa cells, owning the highest *KDM3A* cassion, were chosen for the following expresses.

Next, sh-KDM3A 1# and sh-KDM3A 2# were transfected into HeLa and SiHa cells, and they both showed fective interference on KDM3A expression (Figure 2C and D). The sh-KDM3A 1# with a better interfering efficacy was chosen for further experiments. After

Table 2 Correlations Between the Clinicopath gic Characteristics and KDM3A Expression in Patients with Cervical Cancer (n=50)

Clinical Variables	ases (n=50)	KDM3A Expression	KDM3A Expression	
		Low (n=25)	High (n=25)	
Age	(n=37) <45 (n=13)	21 (56.76%) 4 (30.77%)	16 (43.24%) 9 (69.23%)	0.1963
Tumor size	≥4 cm (n=21) <4 cm (n=29)	12 (38.71%) 13 (44.83%)	19 (61.29%) 16 (55.17%)	0.7938
Lymphatic metastasis	Yes (n=12) No (n=38)	2 (16.67%) 23 (60.53%)	10 (83.33%) 15 (39.47%)	0.0181*
Differentiation Grade	Well (n=14) Moderate (n=24) Poor (n=12)	11 (78.57%) 14 (58.33%) 3 (25%)	3 (21.43%) 10 (41.67%) 9 (75%)	0.0221*
FIGO stage	Stage I (n=17) Stage II (n=33)	11 (64.71%) 13 (39.39%)	6 (35.29%) 20 (60.61%)	0.1359

Notes: Enumeration data were analyzed by Fisher's exact test; *P<0.05.

Abbreviations: KDM3A, lysine demethylase 3a; FIGO, Federation of Gynecology and Obstetrics.





Figure 2 Kin, do not KDM3A-suppresses CC cell growth. mRNA (A) and protein (B) expression of KDM3A in H8 and CC cell lines (HT-8, CaSki, HeLa, and SiHa) determined by the PCR and Western blot analysis, respectively; mRNA (C) and protein (D) expression of KDM3A in HeLa and SiHa cells after sh-KDM3A 1# and sh-KDM3A 2# transfer in measured by T-qPCR and Western blot analysis, respectively; (E) proliferation of CC cells determined by the CCK-8 method; (F) colony formation ability of CC cells; (G) pression of apoptosis-related factors Bax and Bcl-2 in CC cells determined by RT-qPCR; (H) apoptosis rate of CC cells determined by TUNEL. In panels (A-D, F-H), data were analyzed by one-way ANOVA, while data in panel (E) were analyzed by two-way ANOVA, followed by Tukey's multiple comparison test. *P<0.05, **P<0.01 compared to H8; *P<0.05 compared to sh-NC.

KDM3A knockdown, the proliferation ability according to the CCK-8 assay, and the colony formation ability of cells were notably reduced (Figure 2E and F). As for cell apoptosis, the RT-qPCR results identified an increase in *Bax* (pro-apoptotic) expression, with

a decline in *Bcl-2* (anti-apoptotic) expression upon *KDM3A* knockdown (Figure 2G). More obviously, the TUNEL staining results showed that the apoptosis rate of cells was notably enhanced after sh-KDM3A administration (Figure 2H).



angio Figure 3 Knockdown of KDM3A inhibits metastasis of CC cells VECs. (A) Expression of EMT-related factors in HeLa and SiHa cells determined by esis by d-healing RT-qPCR; (B) migration ability of CC cells evaluated by a w ay; (C) in on ability of CC cells measured by a Transwell assay; (**D**) angiogenesis ability of HUVECs in different conditioned medium determined by a anels, data were compared by one-way ANOVA. #P<0.05 compared to sh-NC. forma

Knockdown of KDM3A Inhits Meta tasis of CC Cells and Angiogenesis **HUVECs**

We further explored the levan of *KDM3A* with the metastasis of CC cells. First exp. from of the EMT-related factors dentified an increase in was measured √ RT-PCR, v dine in the expression of N-cadherin E-cadherin hile a A KDM3A knockdown (Figure 3A). In addition, the would healing assay results suggested that the migration of cells was notably decreased when KDM3A was suppressed (Figure 3B). Similarly, the invasive potential of CC cells was reduced following KDM3A downregulation (Figure 3C). These collectively showed that knockdown of KDM3A suppressed metastasis of CC cells. In addition, a tube formation assay was performed by seeding HUVECs in different HeLa and SiHa cell-conditioned medium, which showed that the number of formed tubes by HUVECs was declined after KDM3A knockdown (Figure 3D).

KDM3A Activates ETS1 Through Demethylation of H3K9me2

As discussed above, we hypothesized that KDM3A possibly mediated ETS1 activity through the demethylation and histone modification of H3K9me2. Thereafter, we first explored ETS1 expression in the collected CC tissues. The RT-qPCR results suggested that the mRNA expression of ETS1 was notably increased in tumor tissues relative to the paired adjacent tissues (Figure 4A) and shared a positive correlation with KDM3A expression (Figure 4B). Again, the IHC staining showed an increased positive expression of KDM3A in tumor tissues (Figure 4C).

In HeLa and SiHa cells, we identified that both KDM3A and ETS1 were sub-localized in nuclear according to the immunofluorescence staining (Figure 4D). Then, ETS1 expression in CC cells with stable sh-KDM3A transfection was determined by RT-qPCR, which showed that




Figure 4 KDM3A activates ETS1 through demethylation of H3K9me2. (A TS/ expressio ues and the paired adjacent tissues determined by RT-qPCR; (B) a positive correlation between KDM3A and ETS1 expression; (C) ETS1 e tumor and adjacent tissues evaluated by IHC staining; (D) subcellular localization of ETS1 and KDM3A in cells determined by immunofluorescence staining; (E) of ETS1 in cells determined by RT-qPCR; (F) protein expression of ETS1 and (G) Incractions among KDM3A, H3k9me2, and ETS1 promoter determined by ChIP H3K9me2 in cells after sh-KDM3A administration determined by Western blo nal assays. In panels (A and C), data were compared by the paired *P<0.05 ared to Adjacent; in panel (B), correlation was evaluated by Spearman's rank correlation coefficient, r=0.6545, P<0.0001; data in panels (E and E) ere co e-way ANOVA, while in panel (G) by two-way ANOVA, followed by Tukey's multiple ared by 70.01, @@g comparison test, #P<0.05 compared to sh-KDM3A; @9 <0.001 cd ared to anti-IgG.

\$1 express sh-KDM3A notably inhibit in cells (Figure 4E). Likewise, the protein ression of ETS1 in cells was decreased well after sh-K 13A administration (Figure 4F), ad, interstingly, the protein level of H3K9me2 in cells notably hereased (Figure 4F). was performed to validate the regulated network between KDM3A and ETS1 (Figure 4G). In I la cells, compared to anti-IgG, an enrichment of ETS1 protegree was found in the immunoprecipitates combined by anti-KDM3A. Following sh-KDM3A administration, the enrichment of ETS1 promoter sequence in the precipitates by anti-KDM3A was notably reduced. In SiHa cells, we found that, compared to anti-IgG, anti-H3KPme2 enriched the ETS1 promoter sequence in the precipitates, while this enrichment was further strengthened upon KDM3A knockdown. These results showed that KDM3A promotes ETS1 transcription through the demethylation and histone modification of H3K9me2.

Overexpression of ETS1 Blocks the Inhibition of Sh-KDM3A on CC Cells

To validate the implication of ETS1 in the KDM3A mediation, overexpression of ETS1 was further introduced into CC cells in the presence of KDM3A knockdown, and the transfection efficacy was, again, confirmed by RT-qPCR and Western blot assays (Figure 5A and B). Then, the CCK-8 method showed that the proliferation of cells suppressed by sh-KDM3A was recovered upon ETS1 overexpression (Figure 5C). Next, the flow cytometry suggested that the apoptosis rate of cells was reduced by the further upregulation of ETS1 (Figure 5D). In addition, the migration and invasion abilities of cells reduced by sh-KDM3A were recovered upon ETS1 overexpression (Figure 5E and F). Moreover, HUVECs were sorted in the conditioned medium of CC cells with stable transfection of oe-ETS1, after which the angiogenesis ability of cells suppressed by sh-KDM3A was notably recovered (Figure 5G).

OncoTargets and Therapy 2020:13 submit your manuscript | www.dovepress.com | 11965

Liu et al Dovepress




Figure 5 Overexpression of ETS1 blocks the inhibition of sh-KDM3A on CC cells. (A and B) Transfection efficacy of oe-ETS1 in cells determined by RT-qPCR and Western blot analysis, respectively; (C) proliferation ability of cells measured by colony formation assay; (D) apoptosis rate of cells measured after ETS1 overexpression determined by flow cytometry; migration (E) and invasion (F) abilities of cells determined by wound-healing and Transwell assays, respectively; (G), angiogenesis ability of cells determined by tube formation assay. Data were analyzed by one-way ANOVA, followed by Tukey's multiple comparison. *P<0.05 compared to sh-KDM3A+oe-NC.

ETS1 Transcriptionally Activates KIF14

As mentioned above, *ETS1* has been reported to transcriptionally activate *KIF14*, 12 an oncogene in CC. 13 First,

mRNA expression of *KIF14* in the collected tissues from CC patients was determined, which exhibited that the KIF14 expression was notably increased in the tumor




Figure 6 ETS/transcriptionally activates KIF14. (A) KIF14 expression in tumor and adjactivates tissues dete ned by RT-qPCR; (B) a positive correlation between ETS1 and KIF14 expression; (C) KIF14 expression in tumor and adjacent tissues me by IHC stail 4 expression in HeLa and SiHa cells after sh-KDM3A or oe-ETS1 administration determined by RT-qPCR; (E) putative binding sites between KIEL4 predicted on Jaspar; (F), the binding site with highest score used for luciferase ChIP (H) assay. In panels (A and C), data were analyzed by paired t-test while assay; (G and H), binding relationship between ETS1 and KIF14 Promoter va ted by data in panel (H) by unpaired t-test, **P<0.01 compared to Adjacent, \$\$P<0.0 ed to anu-lgG; in panel (**B**), correlation was evaluated by Spearman's rank correlation coefficient, r=0.6484, P<0.0001; data in panels (D and G) w way ANOVA, #P<0.05 compared to sh-NC, &P<0.05 compared to sh-KDM3A+oe-NC, ared by @P<0.05 compared to Promoter+oe-NC.

adjacen ssues (Figure tissues compared to the matched 6A) and positively associ with ETS (Figure 6B). Again, the IHC stains, intensity of KIF14 was notably enhanced a tumor tissues igure 6C).

We then measured mRN expression of *KIF14* in cells was found that the KIF14 expresafter different transfec by shappy of but then recovered by the further aministry on of occ TS1 (Figure 6D). Then, the sites be een ETS1 and the promoter region of KIF14 we predicted on Jaspar (http://jaspar.genereg.net/) (Figure 6E). The the binding site with the highest score (Figure 6F) was selected for luciferase assay to validate the binding relationship. The Promoter was co-transfected with oe-NC or oe-ETS1 in 293T cells. After 48 hours, the luciferase activity of Promoter was notably increased by oe-ETS1 (Figure 6G). In addition, a ChIP assay was performed, which found an enrichment of KIF14 promoter was found in the precipitates by anti-ETS1 (Figure 6H), indicating a direct binding relationship between ETS1 and the promoter of KIF14.

KIF14 Activates the Hedgehog Signaling Pathway and Promotes CC Progression

KIF14has been documented as a positive regulator of the Hedgehog signaling pathway, 14 whose activation may lead to further development of CC. 15,16 To explore whether KIF14 mediates this signaling pathway in CC, oe-KIF14 was administrated into CC cells, and the successful transfection was validated by RT-qPCR (Figure 7A). Then, the expression of Hedgehog-signaling marker proteins Gli1 and Gli3 was measured by Western blot analysis, which suggested that KIF14 led to a notable increase in the expression of the two proteins (Figure 7B), namely, activating the Hedgehog signaling pathway.

Further, the EdU labeling assay results showed that the EdU-positive rate in CC cells was increased by oe-KIF14 (Figure 7C), while the apoptosis rate of cells was reduced (Figure 7D). In addition, the migratory and invasive potentials of CC cells were promoted upon KIF14 upregulation (Figure 7E and F). Moreover, the angiogenesis ability of Liu et al Dovepress




Figure 7 KIF14 activates the Hedgehog signaling pathy and procession. (A) Transfection efficacy of oe-KIF14 determined by RT-qPCR; (B) protein levels of Gli1 and Gli3 in cells determined by Western blot of ysis; (C) DN application in cells determined by EdU staining; (D) apoptosis rate in cells determined flow cytometry; migration (E) and invasion (F) abilities of cells determined by wound-reling and Transwell assays; (G) angiogenesis ability of HUVECs determined by tube formation assay. Data were analyzed by one-way ANOVA, *P J 5 conced to oe-NC.

HUVECs cultivated in anditioned medium with stable transfection of oe-KIK was in reased (Figure 7G).

Activation of Findgeling Jocks the Inhibiting Role of Sh-KDM3A in CC

To further valies one involvement of Hedgehog in the above events, a rescue experiment was performed through additional administration of a Hedgehog-specific agonist Sag1.5 in cells pre-treated with sh-KDM3A. Then, it was found that this signaling pathway was notably activated (Figure 8A). Thereafter, the colony formation assay results showed that the proliferation of HeLa and SiHa cells inhibited by sh-KDM3A was recovered by Sag1.5 (Figure 8B). In addition, the promotion on cell apoptosis, and the suppression of sh-KDM3A on cell migration and invasion as well as angiogenesis ability of HUVECs were all blocked by the further usage

of Sag1.5 (Figure 8C–F). These results indicated that Hedgehog is a important downstream effector of *KDM3A* in CC progression.

Sh-KDM3A Suppresses Tumor Growth in vivo

HeLa and SiHa cells with stable sh-KDM3A transfection were implanted into the ventral side of mice through a subcutaneous injection. The tumor volume was recorded since the 10th day at a 5-day interval (Figure 9A), which showed that knockdown of *KDM3A* suppressed growth of xenograft tumors in mice. On the 30th day, the mice were euthanized and the tumor tissues were collected and weighed. Again, the tumor weight was reduced upon *KDM3A* knockdown (Figure 9B). Furthermore, the IHC staining results showed that the staining intensity of




Figure 8 Activation of Hedgehog blocks the publicing roll sh-KDM3A in CC. (A) Protein levels of Gli1 and Gli3 in cells determined by Western blot analysis; (B) proliferation of CC cells determined by control formation ass. (C) apoptosis rate of cells measured by TUNEL assay; migration (D) and invasion (E) abilities of cells determined by wound-healing and Transcell assay; (F) angiogen ability of HUVECs determined by tube formation assay. Data were analyzed by one-way ANOVA, *P<0.05 compared to sh-KDM3A+DM3.

KDM3A, ETS1, Kh 1, Co 1, and Gli3 was notably reduced in the tumor cases from mices applanted with cells with stable sh xDM3. transfer of (Figure 9C). These results showed out shows the properties tumor growth in vivo.

Discussion

As a leading cause of cancer related death among females, CC remains a huge healthy concern in the modern society, especially in those low-income countries,² owing to the current limitation in effective treatments. Researchers have made great efforts to explore novel molecular mechanisms and to develop promising factors with prognostic or therapeutic values to overcome the typical malignant behaviors from proliferation to metastasis.^{17–19} Methylation of

histone lysine is crucial for epigenetic correlated gene expression profiles in cancer.²⁰ In this study, we validated an interaction network involving *KDM3A/ETS1/KIF14*, in which *KDM3A* governs *ETS1*-mediated *KIF14* transcription to promote CC growth in either cell and animal models with the further involvement of the Hedgehog signaling pathway.

The *KDM3A* has been reviewed as a promising target for human cancer treatment.⁸ Its oncogenic role has been well demonstrated.^{21–23} Here, the initial finding of the current study was that *KDM3A* was highly expressed in the collected tumor tissues from CC patients, and it led to a dismal 5-year survival rate, increased lymphatic metastasis, and decreased tumor differentiation rate in patients.

OncoTargets and Therapy 2020:13




Figure 9 Sh-KDM3A suppresses tumor growth in vivo. (A) Tumor volume growth by time (n=5); (**B**) weight of tumors in mice on the 30th day; (**C**) expression of KDM3A, ETS1, KIF14, Gli1, and Gli3 in tissues of xenograft tumor staining. Data were analyzed by one-way (panel C) or two-way (panels A and B) ned by ANOVA. *P<0.05, **P<0.01 compared to sh-NC.

Similarly, abundant expression of K M3A has en noted as an independent unfavorable for patients we pancreatic tumor²⁰ and colorectal cancer²⁴ an epithelial ovarian cancer. 25 A high-expression profile of KL 33A was also found in CC cell line. In the sllowing loss-of-function studies, we observed that KDM3 suppressed growth of H and 51Ha cells. In addition, and metastatic ren. an increase the propoptotic actor Bax and the epithelial marker E-cac ri while a decline in the anti-apoptotic factor Bcl-2 and mesenchymal markers N-cadherin and Vimentin suggested at sh-KDM3A promoted apoptosis while suppressing EMT in CC cells in a cellular perspective. In addition, angiogenesis, a hallmark of cancers that is crucial for tumor growth and metastasis, 26 was found to be suppressed as well upon KDM3A downregulation.

KDM3A catalyzes the demethylation of H3K9me1/me2 in vivo and in vitro with a preference for dimethylated transcriptional residues, therefore governing activation. 8,20,27,28 Intriguingly, studies have noted that

KDM3A could control the transcriptional activation of ETS1 in a similar manner. 9,29 ETS1 has been noted as an important oncogene and a treating target in multiple malignancies including breast cancer, 30,31 ovarian cancer, 32,33 and CC as well. 11,34 To validate this potential interaction between KDM3A and ETS1, we first identified nuclearlocalization of KDM3A and ETS1 in CC cells, and then a positive correlation between KDM3A and ETS1 was identified. Further, the ChIP assays were performed, which suggested that ETS1 promoter sequences were enriched by either anti-KDM3A or anti-H3K9me2. On this basis, we found that artificial overexpression of ETS1 blocked the inhibitory roles of sh-KDM3A in CC cell growth, suggesting that ETS1 is possibly responsible for the pro-oncogenic role of KDM3A in CC cells.

We then observed a positive relevance between ETS1 and KIF14 expression in the collected tissues and HeLa and SiHa cells. Then, the ChIP and luciferase assays suggested that as a transcription factor, ETS1 had a direct binding relationship




Figure 10 Diagram presentation of the molecular mechanism. KDM3A encourages the transcription of Exthrough the demethylation and histone modification of H3K9me2, while ETS1 further binds to the promoter region of KIF14 to promote its transcription activity, which is tracted the Hedgehog signaling pathway and promote CC progression.

with the promoter sequence with KIF14 and activated its transcription, which was partially in line with the previous report. 12 KIF4 is a potent oncogene participating development of multiple cancers. For instance, it was a ciated with the metastasis and tumor progra poor treating outcome in gastric carer³⁵ and prostal cancer.³⁶ As for in CC, it was reported prognosis and chemoresistance Here, after identification of the high-expression profil of \ 714 in collect d tissues, we noticed that overexpession of 1/14 promoted the malignant behaviors CC cells, which lidated its oncogenic function in . Intrigungly, KIF14 was documented the Hed nog signaling pathway. as a positive regulator Here, we fund KIFI projected the expression of Gli1 and Gli express in. This signaling pathway, first identified in fruit it is a highly conserved pathway responsible for signal transaction from cell membrane to nucleus, which plays crucial functions for embryonic development and is also implicated in cancer progression.^{37–39} This is also applied in CC, where the Hedgehog was found to be correlated with radioresistance, 40 proliferation and survival, 41 and EMT and metastasis 16 of CC cells. Importantly, our study noticed that upregulation of the Hedgehog blocked the inhibitory functions of sh-KDM3A in CC cells, implicating its participation in KDM3A-mediated events. potential Consistently, similar results were reproduced in our in vivo

periments, there sh-KDM3A suppressed the growth of xe. graft to for in nude mice and the IHC staining intensity of *ETS1*, *KIF14*, Gil1, and Gil3 in the collected tumor tissues. conclude, our experimental results provided evidence that *KDM3A* promotes CC growth in either cell and animal models through triggering *ETS1*-mediated *KIF14* transcription and the further upregulation the Hedgehog signaling pathway (Figure 10). This study may offer new understandings in CC progression and provide novel thoughts into CC treatment.

Data Sharing Statement

All the data generated or analyzed during this study are included in this published article.

Funding

There is no funding to report.

Disclosure

The authors declare no conflicts of interest in this work.

References

 Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2018;68(6):394–424. doi:10.3322/caac.21492

OncoTargets and Therapy 2020:13

Liu et al **Dove**press

2. Shrestha AD, Neupane D, Vedsted P, Kallestrup P. Cervical cancer prevalence, incidence and mortality in low and middle income countries: a systematic review. Asian Pac J Cancer Prev. 2018;19(2):319-324.

- 3. Zheng J, Dai X, Chen H, Fang C, Chen J, Sun L. Down-regulation of LHPP in cervical cancer influences cell proliferation, metastasis and apoptosis by modulating AKT. Biochem Biophys Res Commun. 2018;503(2):1108–1114. doi:10.1016/j.bbrc.2018.06.127
- 4. Papatla K, Houck KL, Hernandez E, Chu C, Rubin S. Second primary uterine malignancies after radiation therapy for cervical cancer. Arch Gynecol Obstet. 2019;300(2):389-394.
- 5. Ayen A, Jimenez Martinez Y, Boulaiz H. Targeted gene delivery therapies for cervical cancer. Cancers. 2020;12:5. doi:10.3390/ cancers12051301
- 6. Audia JE, Campbell RM. Histone modifications and cancer. Cold Spring Harb Perspect Biol. 2016;8(4):a019521. doi:10.1101/cshperspect.
- 7. Wang T, Luo R, Li W, et al. Dihydroartemisinin suppresses bladder cancer cell invasion and migration by regulating KDM3A and p21. J Cancer. 2020;11(5):1115-1124. doi:10.7150/jca.36174
- 8. Yoo J, Jeon YH, Cho HY, et al. Advances in histone demethylase KDM3A as a cancer therapeutic target. Cancers. 2020;12:5. doi:10.3390/cancers12051098
- 9. Sechler M, Parrish JK, Birks DK, Jedlicka P. The histone demethylase KDM3A, and its downstream target MCAM, promote Ewing Sarcoma cell migration and metastasis. Oncogene. 2017;36 (29):4150-4160. doi:10.1038/onc.2017.44
- 10. Dittmer J. The role of the transcription factor Ets1 in carcinoma. Semin Cancer Biol. 2015;35:20–38. doi:10.1016/j.semcancer.2015.09.010
- 11. Liao H, Pan Y, Pan Y, et al. MicroRNA874 is downregulated in cervical cancer and inhibits cancer progression by directly targeting ETS1. Oncol Rep. 2018;40(4):2389-2398.
- 12. Xu H, Zhao G, Zhang Y, et al. Long non-coding RNA PAXIP1-AS1 facilitates cell invasion and angiogenesis of glioma by recruit transcription factor ETS1 to upregulate KIF14 expression. J Ex Clin Cancer Res. 2019;38(1):486. doi:10.1186/s13046-019-1474-7
- 13. Wang W, Shi Y, Li J, Cui W, Yang B. Up-regulation of KIF edictor of poor survival and a novel prognostic biomarker of ice to paclitaxel treatment in cervical cancer. Biosci Rep. 2
- 14. Pejskova P, Reilly ML, Bino L, et al. KIF14 conti regulation of Aurora A and is important or Hedg signaling. 11904107 J Cell Biol. 2020;219:6. doi:10.1083/jc
- 15. Wang YF, Yang HY, Shi XQ Ŵa Y. Upregu microRNA-129-5p inhibits cell invasion, mig. on and tumor angiogenesis by inhibiting ZIC2 downregulation f the Hedgehog signaling pathway in cerv al cancer. Cancer Bio Ther. 2018;19 80/15384 /.2018.1491497 (12):1162–1173. doi:104
- SHH gene silencing suppresses 16. Zhang F, Ren CC, Liu et proliferation, invasion, and migration epithelial-mesench d transi redgehog signaling pathway. of cervical cap g th / repre cell (5):3829-2/ n. 2018;1 Zhen . doi:10.1002/jcb.26414 J Cell Bioc
- TRIP4 promotes tumor growth and 17. Che Y, D. ates radiosensitivity of cervical cancer by activatmetastasis an AKT, and hTERT signaling. Cancer Lett. ing MAPK, I 2019;452:1-13. doi 1016/j.canlet.2019.03.017
- 18. Jiang C, Xu R, Li XX, et al. p53R2 overexpression in cervical cancer promotes AKT signaling and EMT, and is correlated with tumor progression, metastasis and poor prognosis. Cell Cycle. 2017;16(18):1673-1682.
- 19. Zeng YT, Liu XF, Yang WT, Zheng PS. REX1 promotes EMT-induced cell metastasis by activating the JAK2/ STAT3-signaling pathway by targeting SOCS1 in cervical cancer. Oncogene. 2019;38(43):6940-6957. doi:10.1038/s41388-019-0906-3
- 20. Dandawate P, Ghosh C, Palaniyandi K, et al. The histone demethylase KDM3A, increased in human pancreatic tumors, regulates expression of DCLK1 and promotes tumorigenesis in mice. Gastroenterology. 2019;157(6):1646–1659 e1611. doi:10.1053/j. gastro.2019.08.018

21. He C, Yu L, Ding L, Yao H, Chen Y, Hao Y. Lysine demethylase KDM3A regulates nanophotonic hyperthermia resistance generated by 2D silicene in breast cancer. Biomaterials. 2020;255:120181. doi:10.1016/j.biomaterials.2020.120181

- 22. Ramadoss S, Guo G, Wang CY. Lysine demethylase KDM3A regulates breast cancer cell invasion and apoptosis by targeting histone and the non-histone protein p53. Oncogene. 2017;36(1):47–59. doi:10.1038/onc.2016.174
- 23. Ramadoss S, Sen S, Ramachandran I, Roy S, Chaudhuri G, Farias-Eisner R. Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance. Oncogene. 2017;36 (11):1537-1545. doi:10.1038/onc.2016.320
- 24. Liu J, Liang T, Zhangsun W. KDM3A is associated with tumor metastasis and modulates colorectal cancer cell migration and 25. doi:10.1016/j. invasion. Int J Biol Macromol. 2019;126 ijbiomac.2018.12.105
- 25. Yamada D, Kobayashi S, Yamamoto , et al. Role d he hypoxiarelated gene, JMJD1A, in hepatocellu. carcinoma: c ical impact on recurrence after hepatic rection, And 2012;19(3): urg Onco S355–364. doi:10.1245/s10 4-011-1797-x
- 26. Li X, Chen C, Dai Y, et Cinobut in suppres colorectal cancer angiogenesis by disrupt. the dothelial mammalian target of actor lal a axis. Cancer Sci. rapamycin/hypoxi nducible 3988 11/c2 2019;110(5):17 1734. doi:10.
- regulation of lung cancer cell 27. Li Z, Xia J Xu Y. Epigen .ng proliferation and my tion by the chromatin remodeling protein ogenesis. 20 8(11):66. doi:10.1038/s41389-019-0174-7
- LL, Peterle GT, Dos antos M, et al. JMJD1A, H3K9me1, K9me2 and ADM expression as prognostic markers in oral and mous cell carcinoma. PLoS One. 2018;13(3): pharyngeal so 4884
- er M, Parrish JK, et al. KDM3A/Ets1/MCAM axis promotes growth and metastatic properties in Rhabdomyosarcoma. Cancer. 2020;11(1-2):53-65.
- Kim C, Kwon HK, Lee CG, et al. Upregulation of Ets1 expression by NFATc2 and NFKB1/RELA promotes breast cancer cell invasiveness. Oncogenesis. 2018;7(11):91. doi:10.1038/s41389-018-0101-3
- Wu M, Liu X, Jin W, et al. Targeting ETS1 with RNAi-based supramolecular nanoassemblies for multidrug-resistant breast cancer therapy. J Control Release. 2017;253:110–121.
- 32. Kleemann M, Schneider H, Unger K, et al. Induction of apoptosis in ovarian cancer cells by miR-493-3p directly targeting AKT2, STK38L, HMGA2, ETS1 and E2F5. Cell Mol Life Sci. 2019;76(3):539-559.
- 33. Tomar S, Plotnik JP, Haley J, et al. ETS1 induction by the microenvironment promotes ovarian cancer metastasis through focal adhesion kinase. Cancer Lett. 2018;414:190–204. doi:10.1016/j.canlet.2017.11.012
- 34. Kori M, Yalcin Arga K. Potential biomarkers and therapeutic targets in cervical cancer: insights from the meta-analysis of transcriptomics data within network biomedicine perspective. PLoS One. 2018;13(7): e0200717.
- 35. Yang Z, Li C, Yan C, et al. KIF14 promotes tumor progression and metastasis and is an independent predictor of poor prognosis in human gastric cancer. Biochim Biophys Acta Mol Basis Dis. 2019;1865(1):181-192. doi:10.1016/j.bbadis.2018.10.
- 36. Zhang Y, Yuan Y, Liang P, et al. Overexpression of a novel candidate oncogene KIF14 correlates with tumor progression and poor prognosis in prostate cancer. Oncotarget. 2017;8(28):45459-45469. doi:10.18632/oncotarget.17564
- 37. Salaritabar A, Berindan-Neagoe I, Darvish B, et al. Targeting Hedgehog signaling pathway: paving the road for cancer therapy. Pharmacol Res. 2019;141:466-480. doi:10.1016/j.phrs.2019.01.014
- 38. Skoda AM, Simovic D, Karin V, Kardum V, Vranic S, Serman L. The role of the Hedgehog signaling pathway in cancer: A comprehensive review. Bosn J Basic Med Sci. 2018;18(1):8-20. doi:10.17305/ bjbms.2018.2756

- Xin M, Ji X, De La Cruz LK, Thareja S, Wang B. Strategies to target the Hedgehog signaling pathway for cancer therapy. *Med Res Rev.* 2018;38(3):870–913. doi:10.1002/med.21482
- Liu C, Wang R. The roles of hedgehog signaling pathway in radioresistance of cervical cancer. *Dose Response*. 2019;17 (4):1559325819885293. doi:10.1177/1559325819885293
- Samarzija I, Beard P. Hedgehog pathway regulators influence cervical cancer cell proliferation, survival and migration. *Biochem Biophys Res Commun.* 2012;425(1):64–69. doi:10.1016/j.bbrc.2012.07.051



OncoTargets and Therapy

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic

agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

 $\textbf{Submit your manuscript here:} \ \texttt{https://www.dovepress.com/oncotargets-and-therapy-journal}$

Dovepress

submit your manuscript | www.dovepress.com